XML 148 R5.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Shareholder Note Receivable
Accumulated Deficit
Redeemable Convertible Preferred Stock
Preferred Stock
Common Stock Subject to Possible Redemption
Common Stock
Previously Reported
Previously Reported
Common Stock
Previously Reported
Treasury Stock
Previously Reported
Additional Paid-In Capital
Previously Reported
Accumulated Deficit
Previously Reported
Redeemable Convertible Preferred Stock
Retroactive Application of Recapitalization
Retroactive Application of Recapitalization
Common Stock
Retroactive Application of Recapitalization
Treasury Stock
Retroactive Application of Recapitalization
Additional Paid-In Capital
Retroactive Application of Recapitalization
Redeemable Convertible Preferred Stock
Adjusted Balance
Adjusted Balance
Common Stock
Adjusted Balance
Additional Paid-In Capital
Adjusted Balance
Accumulated Deficit
Balance at the beginning at Dec. 31, 2022 $ (70,539,000) $ 0 $ 0 $ 209,928,000   $ (280,467,000) $ 64,020,000                                
Balance at the beginning (in shares) at Dec. 31, 2022   6,143,294 124,225       16,498,279                                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                              
Exercise of stock options (in dollars) $ 1,000     1,000                                      
Exercise of stock options (in shares) 1,000 1,000                                          
Reissuance of Shadow Preferred in Pay-to-Play Pull Through Exchange at redemption value (In dollars) $ (109,327,000)     (109,327,000)     $ 109,327,000                                
Reissuance of Shadow Preferred in Pay-to-Play Pull Through Exchange at redemption value (in shares)   (2,799,634)         27,996,424                                
Reissuance of common stock in common rights offering (in shares)   8,109,693                                          
Issuance of common stock upon release of restricted stock units   6,000,000                                          
Pay-to-Play financing charges 35,771,000     35,771,000                                      
Debt financing charge on convertible notes 2,640,000     2,640,000                                      
Stock-based compensation 2,483,000     2,483,000                                      
Net income (loss) (87,589,000)         (87,589,000)                                  
Balance at the ending at Dec. 31, 2023 (226,560,000) $ 0 $ 0 141,496,000   (368,056,000) $ 173,347,000   $ (226,560,000)     $ 141,496,000 $ (368,056,000) $ 173,347,000 $ 173,347,000 $ 5,000   $ 173,342,000 $ (173,347,000) $ (53,213,000) $ 5,000 $ 314,838,000 $ (368,056,000)
Balance at the ending (in shares) at Dec. 31, 2023   17,454,353 124,225       44,494,703     13,613,269 96,887     34,712,525   34,712,525         48,325,794    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                              
Retroactive application of recapitalization                                 $ (96,887)            
Retroactive application of recapitalization (in shares)                                     (34,712,525)        
Stock-based compensation 337,000     337,000                                      
Net income (loss) (16,743,000)         (16,743,000)                                  
Balance at the ending at Mar. 31, 2024 (69,619,000) $ 5,000   315,175,000   (384,799,000)                                  
Balance at the ending (in shares) at Mar. 31, 2024   48,325,794                                          
Balance at the beginning at Dec. 31, 2023 (226,560,000) $ 0 $ 0 141,496,000   (368,056,000) $ 173,347,000   (226,560,000)     141,496,000 (368,056,000) $ 173,347,000 173,347,000 $ 5,000   173,342,000 $ (173,347,000) (53,213,000) $ 5,000 314,838,000 (368,056,000)
Balance at the beginning (in shares) at Dec. 31, 2023   17,454,353 124,225       44,494,703     13,613,269 96,887     34,712,525   34,712,525         48,325,794    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                              
Exercise of stock options (in dollars) $ 98,000     98,000                                      
Exercise of stock options (in shares) 65,646 65,646                                          
Stock-based compensation $ 3,847,000     3,847,000                                      
Net income (loss) $ (61,195,000)         (61,195,000)                                  
Balance at the end (in shares) at Dec. 31, 2024 0                                            
Balance at the ending at Dec. 31, 2024 $ (283,810,000) $ 0 $ 0 145,441,000   (429,251,000) $ 173,347,000   $ (283,810,000)     $ 145,441,000 $ (429,251,000) $ 173,347,000           $ (110,463,000) $ 5,000 $ 318,783,000 $ (429,251,000)
Balance at the ending (in shares) at Dec. 31, 2024   17,519,999 124,225       44,494,703     13,663,527 96,887     34,712,525   34,712,525         48,376,052    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                              
Issuance of common stock to advisors, Value 300,000     300,000                                      
Issuance of common stock to advisors, Shares   94,949                                          
Conversion of convertible notes (in shares)   31,433,259                                          
Retroactive application of recapitalization                             $ 173,347,000 $ 5,000   $ 173,342,000 $ (173,347,000)        
Retroactive application of recapitalization (in shares)                                 (96,887)   (34,712,525)        
Temporary equity Merger and PIPE financing, Shares               2,854,242                              
Temporary equity Merger and PIPE financing, Value               $ 33,061,000                              
Conversion of convertible notes 314,334,000 $ 3,000   314,331,000                                      
Net exercise of warrants 75,057,000 $ 1,000   75,056,000                                      
Net exercise of warrants (in shares)   7,505,657                                          
Merger and PIPE financing, Shares   11,408,957                                          
Merger and PIPE financing, Value (126,164,000) $ 1,000   (117,411,000) $ (8,754,000)                                    
Payment of Shareholder note receivable 200,000       200,000                                    
Issuance of common stock warrants 167,000     167,000                                      
Stock-based compensation 11,040,000     11,040,000                                      
Net income (loss) (147,761,000)         (147,761,000)                                  
Balance at the end at Mar. 31, 2025 $ 33,061,000             $ 33,061,000                              
Balance at the end (in shares) at Mar. 31, 2025 2,854,242             2,854,242                              
Balance at the ending at Mar. 31, 2025 $ 16,710,000 $ 10,000   $ 602,266,000 $ (8,554,000) $ (577,012,000)                                  
Balance at the ending (in shares) at Mar. 31, 2025   98,818,874